(Q39161582)

English

Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion

scientific article published on September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion (English)

1 reference

Europe PubMed Central

9 September 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Wei Wei

1

1 reference

Europe PubMed Central

9 September 2017

He Huang

2

1 reference

Europe PubMed Central

9 September 2017

Shan Zhao

3

1 reference

Europe PubMed Central

9 September 2017

Wei Liu

4

1 reference

Europe PubMed Central

9 September 2017

Chuan-Xu Liu

5

1 reference

Europe PubMed Central

9 September 2017

Li Chen

6

1 reference

Europe PubMed Central

9 September 2017

Jun-Min Li

7

1 reference

Europe PubMed Central

9 September 2017

Ying-Li Wu

8

1 reference

Europe PubMed Central

9 September 2017

Hua Yan

9

1 reference

Europe PubMed Central

9 September 2017

publication date

1 September 2013

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

18

1 reference

Europe PubMed Central

9 September 2017

9

1 reference

Europe PubMed Central

9 September 2017

1060-1070

1 reference

Europe PubMed Central

9 September 2017

https://scigraph.springernature.com/pub.10.1007/s10495-013-0854-2

0 references

Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Chronic myeloid leukaemia as a model of disease evolution in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways.

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

JAK-STAT signaling activated by Abl oncogenes

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Cytotoxic sesquiterpene lactones mediate their death-inducing effect in leukemia T cells by triggering apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Antiproliferative sesquiterpene lactones from the roots of Inula helenium

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Cytotoxic Michael-type amine adducts of alpha-methylene lactones alantolactone and isoalantolactone

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Activation of caspases and poly (ADP-ribose) polymerase cleavage to induce apoptosis in leukemia HL-60 cells by Inula racemosa

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Alantolactone inhibits cell proliferation by interrupting the interaction between Cripto-1 and activin receptor type II A in activin signaling pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

The fixed structure of Licochalcone A by alpha, beta-unsaturated ketone is necessary for anti-inflammatory activity through the inhibition of NF-kappaB activation

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Oncoprotein suppression of tumor necrosis factor-induced NF kappa B activation is independent of Raf-controlled pathways

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

p53- and Mdm2-Independent Repression of NF-κB Transactivation by the ARF Tumor Suppressor

1 reference

https://api.crossref.org/works/10.1007%2FS10495-013-0854-2

21 January 2018

Identifiers

10.1007/S10495-013-0854-2

1 reference

Europe PubMed Central

9 September 2017

release_rqt2dnnvxrhd7lnu6gvcewko3y

1 reference

https://api.fatcat.wiki/v0/release/rqt2dnnvxrhd7lnu6gvcewko3y

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

9 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39161582&oldid=2081168471"